Toll-like receptor 7/8

Overview

Toll-like receptors 7 and 8 (TLR7 and TLR8) are single-stranded RNA (ssRNA)-sensing pattern recognition receptors (PRRs) belonging to the toll-like receptor family, a class of innate immune sensors critical for detecting pathogen-associated molecular patterns (PAMPs). Both receptors are endosomal transmembrane glycoproteins expressed predominantly on immune cells, including dendritic cells, monocytes, macrophages, and B cells. TLR7 is preferentially expressed in plasmacytoid dendritic cells, while TLR8 shows higher expression in myeloid dendritic cells and monocytes. Upon binding to viral ssRNA or synthetic agonists, TLR7 and TLR8 signal through the MyD88 adaptor protein, activating NF-κB and IRF transcription factors to drive production of proinflammatory cytokines such as interleukin-6, type I interferons, and other innate immune mediators. Their combined designation as TLR7/8 reflects substantial functional overlap, as dual agonists capable of engaging both receptors — most notably resiquimod (R848) — are widely used in research and clinical development.

TLR7 and TLR8 occupy a central position at the intersection of innate and adaptive immunity. Their activation potently stimulates dendritic cell maturation, enhances antigen cross-presentation, and promotes Th1-polarized adaptive immune responses, properties that have made TLR7/8 agonists attractive as vaccine adjuvants and cancer immunotherapy agents. Conversely, dysregulated or excessive signaling through these receptors — particularly gain-of-function mutations in TLR7 — has been implicated in autoimmune conditions including systemic lupus erythematosus (SLE), positioning TLR7/8 antagonists as a complementary therapeutic avenue. The dual nature of TLR7/8 as both immune activators and drivers of immunopathology makes them high-value targets across oncology, infectious disease, and autoimmunity research.

Recent Publications Summary

Recent publications have explored Toll-like receptor 7/8 as a vaccine adjuvant target, an immunotherapy component, and a therapeutic modulation point in cancer, infection, and autoimmunity. In vaccination studies, a nanovaccine co-encapsulating varicella-zoster virus glycoprotein E with TLR4 agonist MPLA and TLR7/8 agonist imiquimod (IMQ) efficiently targeted draining lymph nodes, enhanced antigen-presenting cell uptake and maturation, and elicited antibody and Th1-biased cellular responses in both young and aged mice, with improved IFN-γ and TNF-α production and reduced Treg and MDSC populations in aged animals 42595179Aug. Similarly, an intranasal liposomal formulation combining TLR4 and TLR7/8 ligands with ovalbumin conferred broad, durable mucosal protection in mice against respiratory threats including SARS-CoV-2, SARS, SHC014 coronavirus, Staphylococcus aureus, Acinetobacter baumannii, and allergens, mediated by persistent antigen-specific memory T cells and alveolar macrophage imprinting 41712698Feb. Covalent conjugation strategies also proved effective: chimeric PRR ligands including TLR4/TLR7 and TLR7/RIG-I combinations amplified innate immune activation and improved antigen-specific responses in murine vaccination models, while intratumoral delivery of a conjugated TLR4/TLR7 ligand produced antitumor activity in melanoma 42087448May.

Several studies focused on TLR7/8 agonists as cancer immunotherapy agents. Resiquimod (R848) was incorporated into multiple delivery systems to improve tumor selectivity and reduce toxicity. A sonochemically activated nanoparticle system used riboflavin tetrabutyrate to trigger thioketal cleavage under ultrasound, releasing active R848 in situ and producing strong antitumor immunity with marked enhancement of tumor-specific T-cell responses and high tumor inhibition in CT26 and 4T1 models 42584258Aug. An injectable thermal-protective hydrogel delivered mitoxantrone and R848 in a dual-responsive manner to support postoperative tumor ablation while limiting thermal injury and modulating the immunosuppressive microenvironment 42374665Jun. Another study developed an ascorbic acid-activatable implantable gel co-delivering a copper-dependent prodrug and R848 for postoperative glioblastoma therapy, where local copper complex formation induced tumoricidal effects and immunogenic cell death while R848 amplified antitumor immunity 41942054Apr. Albumin-bound alkylated resiquimod likewise improved systemic delivery, repolarized tumor-associated macrophages toward an M1 phenotype, activated dendritic cells, increased intratumoral CD8+ T-cell infiltration, and synergized with anti-PD-1 therapy to suppress metastasis and induce complete regressions in some 4T1-bearing mice 41997499Apr. A polymer-based nanodisc platform conjugated with a TLR7/8 agonist also served as a local depot and in situ immunization tool, inhibiting tumor growth, inducing immune memory, and showing synergy with anti-PD-1 42463976Jul.

Other publications examined chemistry, receptor biology, and disease associations of TLR7/8. Small-molecule discovery efforts identified a pyrazolo[1,5-c]quinazoline scaffold with moderate dual TLR7/TLR8 agonist activity and, after optimization, several dual antagonists, expanding structure-activity knowledge for TLR7/8 modulators 42014047Apr. A separate medicinal chemistry program yielded a quinazoline-based selective TLR8 antagonist with low-nanomolar potency and good metabolic stability 41962328Apr. In hepatitis B research, an indole derivative inhibited viral DNA replication and promoted TLR7 downstream cytokines such as IL-12 and IFN-α in human peripheral blood mononuclear cells, with docking and SPR supporting direct TLR7 binding 42001858Apr. Sex-based immune response differences were also highlighted in early-stage melanoma: resiquimod induced stronger conventional dendritic cell activation and cytokine release than the TLR9 agonist agatolimod in female sentinel lymph node cells, suggesting potential value for women in this setting 42093471May. Finally, TLR7 biology was linked to disease mechanisms in a child with autoimmune hemolytic anemia caused by a gain-of-function TLR7 mutation 42067661May, and another glioma study identified TLR8 among key regulators in a neutrophil extracellular trap-associated prognostic model associated with immune evasion and therapy response differences 41740342Feb.

What Changes, What Holds

1. TLR7/8 agonist adjuvants can broaden vaccination strategies to combined innate targeting and mucosal protection
REINFORCES Co-delivery of TLR7/8 agonists with other adjuvant cues or antigen platforms strengthens the established adjuvant role of TLR7/8 rather than changing it. The new work sharpens the baseline by showing that this class can drive durable Th1-skewed responses, dendritic-cell activation, and memory formation across systemic and mucosal settings, including in aged hosts 42595179Aug41712698Feb. It supports use as a vaccine amplifier, but does not alter the underlying receptor biology.

2. Localized and triggerable resiquimod delivery improves tumor immunotherapy without changing the established antitumor rationale
REINFORCES The delivery advances mainly refine how an already recognized TLR7/8 agonist is used in cancer: better localization, lower off-target exposure, and stronger integration with surgery, chemotherapy, or checkpoint blockade. That extends the Overview’s claim that TLR7/8 agonists are attractive cancer immunotherapy agents, and the added immune-memory and macrophage-repolarization findings further support the same direction 42584258Aug41997499Apr. The paragraph adds practical platforms, not a new biological role.

3. New ligands, antagonists, and disease links extend TLR7/8 biology but mostly do not overturn the settled account
NEW DIRECTION Selective TLR8 antagonism, dual agonist/antagonist scaffolds, a hepatitis B-associated TLR7-binding indole, sex-biased responses in melanoma, and a gain-of-function TLR7 mutation in autoimmune hemolytic anemia all widen the map of TLR7/8 use and pathology without displacing the baseline. The only departure from the Overview is that TLR8 now appears as a druggable antagonist target and TLR7 as a disease-linked mutation site beyond SLE 42014047Apr41962328Apr. The glioma prognostic model is a separate biomarker application.

Overview update candidates: selective TLR8 antagonism as a therapeutic modality; TLR7 gain-of-function mutation implicated in autoimmune hemolytic anemia; TLR7-binding indole activity in hepatitis B; sex-based differences in resiquimod-responsive melanoma dendritic-cell activation.